Demonstration of cell-bound and humoral immunity against neuroblastoma cells
about
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesSerum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen.Olfactory neuroblastoma with epithelial and endocrine differentiation transformed into ganglioneuroma after chemoradiotherapy.The role of circulating antibody in the control of metastases.Clinical value of tumour-associated antigens.Recent advances in neuroblastoma.Therapeutic vaccination with tumor cells that engage CD137.Recurrent and metastatic malignant disease: immunological considerations.Tissue T and B cell infiltration of primary and metastatic cancerMixed leukocyte reactivity and leukemia: study of identical siblings.Are observations on tumour viruses in animals applicable to man?Foetal antigens and their role in the diagnosis and clinical management of human neoplasms: a review.The significance of lymphocytic infiltration in neuroblastoma.Glioblastoma multiforme: a controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy.Separation of lymphocytes and macrophages from suspensions of guinea pig peritonitis exudate cells using programmed gradient sedimentation.In vitro induction of tumor-specific immunity. I. Parameters of activation and cytotoxic reactivity of mouse lymphoid cells immunized in vitro against syngeneic and allogeneic plasma cell tumors.RESEARCH ADVANCES IN NEUROBLASTOMA IMMUNOTHERAPY.Immunology and immunotherapy of neuroblastomaStudies of humoral and cell-mediated immunity in human melanomaCirculating immune complexes in sera of children with neuroblastoma: correlation with stage of disease.Serum-mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor-specific antigens.In vitro detection of cytotoxic cellular immunity against tumor-specific antigens by a radioisotopic technique.Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes.Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells.Differentiation of neuroblastoma cells in culture.Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.Curing tumor-bearing mice by shifting a Th2 to a Th1 anti-tumor response.Modification of the immunologic properties of the cell surface.Tumor-directed cellular immunity in malignant melanoma and its modification by surgical treatment.An investigation of cellular components released from human renal cancer and foetal kidney xenografts in nude mice (nu/nu) by cross-immunization of hairy littermate relatives.KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy.Common antigenic component in ovarian carcinomas: demonstration by double diffusion and immunofluorescence techniques.Relation between cellular immunity to nephroblastoma and the phase of the disease.
P2860
Q27008070-E5ACE325-1310-4438-B043-9FCFF311E038Q33280654-8FC5A440-6B8C-49F3-B352-3C937712B143Q34114006-F485F803-F62A-44BC-BE6E-83FD8EE5074AQ34303076-F3BC751E-60AC-4BC1-A093-FBF5B8F1D3F9Q34303095-7F26583F-8DD1-42E6-966D-F0271C9A7A5FQ34826986-9D9D70B9-D70F-40A5-B94E-019EEFD33755Q35071688-4AF16089-5DED-43ED-B985-FC191A0B2CFCQ35145458-3513898A-6C82-40F6-A7AB-A70F656665BAQ35201619-9956D501-A8BA-40A6-99A1-6E93AF2B2E30Q35582024-F07D0ECE-8E29-481E-A14C-B17E095AC92BQ35665279-EA042E6B-B60E-4954-B406-6FB9032986C1Q36039439-7B15F4E9-B5A4-4552-B4A6-5CBA645379CBQ36039464-96D05A0D-340F-4D8F-B001-A93EF01C9EC8Q36039846-767CD373-D24F-4D00-B23E-41D93ACA116AQ36101562-DE533B45-2B7A-498D-A51C-8AD5E28E502DQ36334894-AFAC48E8-0C2C-4180-AF4F-8F0330BE2F5EQ36776358-B0A2645F-E31A-4E84-8F8A-1B86FB1D1917Q36856798-82F7A619-BC50-4D60-A52B-2F9D0C2A4802Q36991945-E1105676-A089-4CA6-A9DC-BE19E3E47772Q37033835-23450C3A-8236-4AAE-88E3-FE530F4DD6A7Q37422761-59C54CAD-0066-41AC-8056-27157A5204ADQ37478983-099818CD-080F-4AA7-9C4E-59A3D81FFAAEQ37479263-C9BA7AA1-E576-4264-BCD5-AAA4B5CBF703Q37641790-A2FEB47C-8AB6-42E7-B0D1-9D168F3D65CEQ38138682-26F9CC38-3904-46CF-A549-C3E930A481AAQ38886708-46B6A3D0-B806-45B0-BBDA-BCEDF3FF1723Q39022359-6AC19677-C6DE-4C24-9DF6-4E4B512393CCQ39185241-B85BB586-A54F-4037-AC25-132C8624EFB0Q41446916-650B5298-DB3E-49E8-AB96-35A7B39DBDCCQ41769475-BB2EE671-698E-43B2-95EB-C5232500646EQ41985731-F360E68B-E025-47BD-9E1D-7C5E18E596F7Q46822132-290DEBBB-0233-4F13-9314-DD4C5B6997B4Q54510422-B0B79F3F-4D4B-477B-ABCB-839E493E6F60Q54692508-482AF46D-88DA-465A-ACEB-BC6BAFA02CB8
P2860
Demonstration of cell-bound and humoral immunity against neuroblastoma cells
description
1968 nî lūn-bûn
@nan
1968年の論文
@ja
1968年学术文章
@wuu
1968年学术文章
@zh-cn
1968年学术文章
@zh-hans
1968年学术文章
@zh-my
1968年学术文章
@zh-sg
1968年學術文章
@yue
1968年學術文章
@zh
1968年學術文章
@zh-hant
name
Demonstration of cell-bound and humoral immunity against neuroblastoma cells
@ast
Demonstration of cell-bound and humoral immunity against neuroblastoma cells
@en
type
label
Demonstration of cell-bound and humoral immunity against neuroblastoma cells
@ast
Demonstration of cell-bound and humoral immunity against neuroblastoma cells
@en
prefLabel
Demonstration of cell-bound and humoral immunity against neuroblastoma cells
@ast
Demonstration of cell-bound and humoral immunity against neuroblastoma cells
@en
P2093
P2860
P356
P1476
Demonstration of cell-bound and humoral immunity against neuroblastoma cells
@en
P2093
Hellström IE
Hellström KE
P2860
P304
P356
10.1073/PNAS.60.4.1231
P407
P577
1968-08-01T00:00:00Z